Dermatology · Concord, NH
NPI
1235572207
Since 2013
Specialty
Dermatology
Code 207N00000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
253 Pleasant St
Concord, NH, 03301
Phone (603) 226-6119
Groups this clinician bills Medicare through
Medicare paid, 2024
$202K
6,322 services
Medicare patients, 2024
1,119
Average age 76
Drug cost, 2024
$2.6M
1,815 prescriptions
Company payments, 2025
$287
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew Kim was code 17003 (destruction skin lesion), 2,130 times for 445 patients. In total Andrew Kim billed 6,322 services in 86 codes, and Medicare paid $202K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,130 | 445 | $1.45 | $3,099 |
| 99214 Office E&M - Established | Office | 879 | 644 | $66.71 | $59K |
| 17000 Destruction Skin Lesion | Office | 798 | 608 | $35.34 | $28K |
| 99213 Office E&M - Established | Office | 774 | 616 | $46.88 | $36K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 430 | 367 | $12.40 | $5,331 |
| 17110 Destruction Skin Lesion | Office | 291 | 237 | $48.19 | $14K |
| 11102 Skin Biopsy | Office | 257 | 223 | $19.72 | $5,069 |
| 17262 Destruction Skin Lesion | Office | 78 | 61 | $67.49 | $5,265 |
| 17004 Destruction Skin Lesion | Office | 77 | 62 | $70.70 | $5,444 |
| 11103 Skin Biopsy | Office | 75 | 52 | $16.82 | $1,261 |
| 12032 Wound Repair - All Levels | Office | 49 | 45 | $119.51 | $5,856 |
| 99212 Office E&M - Established | Office | 36 | 35 | $25.91 | $933 |
| 17282 Destruction Skin Lesion | Office | 33 | 27 | $89.09 | $2,940 |
| 17261 Destruction Skin Lesion | Office | 30 | 29 | $51.35 | $1,540 |
| 99203 Office E&M - New | Office | 26 | 26 | $56.49 | $1,469 |
By year: 2022 $295K for 6,589 services; 2023 $213K for 5,364 services; 2024 $202K for 6,322 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| Q0112 All potassium hydroxide (koh) preparations | 24 | 24 | $5.76 | $138 |
Medicare prescription drug claims, 2024
In 2024, the drug Andrew Kim prescribed most often to Medicare patients was Triamcinolone Acetonide, with 266 prescriptions and refills. In total Andrew Kim wrote 1,815 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 266 | 340 | 176 | $2,191 |
| Clobetasol Propionate Generic | 218 | 236 | 132 | $7,764 |
| Fluorouracil Generic | 181 | 192 | 166 | $13K |
| Ketoconazole Generic | 176 | 205 | 96 | $2,848 |
| Hydrocortisone Generic | 124 | 125 | 89 | $643 |
| Skyrizi Pen Risankizumab-Rzaa | 58 | 153 | 16 | $1.1M |
| Valacyclovir Valacyclovir Hcl | 56 | 82 | 31 | $747 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 46 | 50 | Under 11 | $361K |
| Dupixent Syringe Dupilumab | 43 | 43 | Under 11 | $161K |
| Dupixent Pen Dupilumab | 41 | 41 | Under 11 | $154K |
| Minoxidil Generic | 32 | 86 | Under 11 | $398 |
| Rinvoq Upadacitinib | 29 | 33 | Under 11 | $206K |
| Hydroxychloroquine Sulfate Generic | 28 | 48 | Under 11 | $882 |
| Calcipotriene Generic | 26 | 35 | 12 | $4,114 |
| Doxycycline Hyclate Generic | 24 | 35 | 15 | $759 |
Brand drugs: 329 claims; generic drugs: 1,486 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew Kim $287 ($287 in general payments such as food, travel and fees) from 4 companies. The largest payer was Janssen Biotech, Inc. with $115.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.